Navigation Links
China Sky One Medical, Inc. Announces Guidance for Second Quarter and Full Year 2008
Date:6/10/2008

HARBIN, China, June 10 /Xinhua-PRNewswire-FirstCall/ -- China Sky One Medical, Inc. (Amex: CSY) (''China Sky One Medical,'' ''CSY''), a manufacturer, marketer and distributor of pharmaceutical, medicinal and diagnostic products in China, today announced financial guidance for the second quarter and full-year 2008 periods.

China Sky One Medical, Inc. estimated that second quarter gross revenue would climb 57% over the first quarter of 2008 to $19.5 million and that gross margin for the quarter is expected to be approximately 78%. Net income would reach an estimated $6.4 million, or $0.43 per fully diluted share based on 14,888,310 quarterly diluted shares outstanding as of March 31, 2008, and net margin would be approximately 32.8%. The sharp increase is mainly due to the following factors: First, products introduced from Heilongjiang Tianlong Pharmaceutical, Inc., which China Sky One Medical acquired in March, entered the markets rapidly and have had strong sales. Second, China Sky One has launched advertising promotions for its popular external use products, including Slim Patch Body-Beauty Plaster, Hemorrhoid Ointment, Compound Camphor Cream and Blood Pressure Depress Patches, which have stimulated sales. Finally, the second and third quarters are historically seasonally strong sales periods in the pharmaceutical market.

China Sky One also updated guidance for its full-year 2008 gross revenue and provided guidance for net income and earnings per share. The company expects 2008 gross revenue in the range of $81 million to $83 million and gross margin to be approximately 78.5%. Net income for 2008 is estimated to be between $25.9 million and $26.6 million, or $1.74 to $1.79 per fully diluted share based on 14,888,310 quarterly diluted shares outstanding as of March 31, 2008, and net margin is expected to be approximately 32%. Previously, the company had expected gross revenue in 2008 of approximately $80 million and gross margin to be approximately 78.5%.

''We are confident that we will achieve significant revenue growth going forward as we continue to implement our strategy of hiring direct territory managers and sales agents to further strengthen our distribution channels,'' said Mr. Yan-Qing Liu, Chairman and CEO of China Sky One Medical, Inc. "In addition, we plan to continue with our research and development efforts and to make strategic acquisitions.''

About China Sky One Medical, Inc.

China Sky One Medical, Inc., a Nevada corporation, is a holding company whose principal operations are through its subsidiaries, which are engaged in the manufacturing, marketing and distribution of pharmaceutical, medicinal and diagnostic kit products. Through its wholly-owned subsidiaries, Harbin Tian Di Ren Medical Science and Technology Company (''TDR'') and Harbin First Bio-Engineering Company Limited ("First"), the Company manufactures and distributes over-the-counter pharmaceutical products as its primary revenue source. For more information, visit http://www.skyonemedical.com .

Safe Harbor Statement

Certain of the statements made in the press release constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by the use of forward- looking terminology such as "believe," "expect," "may," "will," "should," "project," "plan," "seek," "intend," or "anticipate" or the negative thereof or comparable terminology. Such statements typically involve risks and uncertainties and may include financial projections or information regarding our future plans, objectives or performance. Actual results could differ materially from the expectations reflected in such forward-looking statements as a result of a variety of factors, including the risks associated with the effect of changing economic conditions in The People's Republic of China, variations in cash flow, reliance on collaborative retail partners and on new product development, variations in new product development, risks associated with rapid technological change, and the potential of introduced or undetected flaws and defects in products, and other risk factors detailed in reports filed with the Securities and Exchange Commission from time to time.

For more information, please contact:

Company Contact:

China Sky One Medical, Inc.

Mr. Liao Xiaoqing, CFO

Tel: +86-0451-53994069

Email: cntiandiren@yahoo.com.cn

Investor Relations Contact:

CCG Elite Investor Relations Inc.

Mr. Crocker Coulson, President

Tel: +1-646-213-1915 (New York)

Email: crocker.coulson@ccgir.com

Website: http://www.ccgelite.com


'/>"/>
SOURCE China Sky One Medical, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Chinas 1-child policy could backfire on its elderly
2. Omnicom Acquires Leading Healthcare Marketing Communications Firm in China
3. Expanding Prevalent Population Will Drive Dramatic Growth for the Asthma Drug Market in China
4. Bridgetech Announces Addition of the Agency for Healthcare Research and Quality as Content Provider in its Development of a Healthcare Web Portal in China
5. China Holdings Appoints Ronald Shon Chairman of Advisory Board to Its Wholly-Owned Subsidiary China Power, Inc.
6. China Bionanometer Industries Corporation Promotes New Cosmetics Product Line in China
7. China Shenghuo Pharmaceutical Holdings, Inc. Begins Full-Scale Launch of 12Ways(R) Chinese Herbal Skin Care Product Line
8. Statement by Mike Leavitt Secretary of Health and Human Services on the United States-China Bilateral Meetings on Food and Drug Safety
9. Supplier Assessments to Help Buyers Identify Reliable China Exporters
10. Study shows lead-based paint problem isnt isolated to China
11. Bracco Announces Initiative to Save Children in China at 2007 Annual Meeting of CGI
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... First ... United States, named Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell ... facility Medical Director of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive ...
(Date:6/25/2016)... ... ... Conventional wisdom preaches the benefits of moderation, whether it’s a matter of ... too high can result in disappointment, perhaps even self-loathing. However, those who set the ... Research from PsychTests.com reveals that behind the tendency to set low expectations ...
(Date:6/24/2016)... ... June 24, 2016 , ... Marcy was in a crisis. Her son James, eight, ... at his family verbally and physically. , “When something upset him, he couldn’t control his ... it. He would throw rocks at my other children and say he was going to ...
(Date:6/24/2016)... ... 24, 2016 , ... Comfort Keepers® of San Diego, CA is excited to ... Recovery® program to drive cancer patients to and from their cancer treatments. Comfort ... quality of life and ongoing independence. Getting to and from medical treatments is ...
(Date:6/24/2016)... ... June 24, 2016 , ... The ... recognize Dr. Barry M. Weintraub as a prominent plastic surgeon and the network’s ... the world, and the most handsome men, look naturally attractive. Plastic surgery should ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... Research and Markets has announced the addition of ... Forecast to 2022" report to their offering. ... date financial data derived from varied research sources to present ... impact on the market during the next five years, including ... sub markets, regional and country level analysis. The report provides ...
(Date:6/23/2016)... , June 23, 2016 Bracket , ... launch its next generation clinical outcomes platform, Bracket eCOA (SM) ... held on June 26 – 30, 2016 in ... first electronic Clinical Outcome Assessment product of its kind to ... #715. Bracket eCOA 6.0 is a flexible platform ...
(Date:6/23/2016)... and BOGOTA, Colombia , June 23, 2016  Astellas today announced the establishment of ... Farma Brasil as the company,s second affiliate in Latin America . ... ... Manager of Astellas Farma Colombia ... ...
Breaking Medicine Technology: